ERBB3 Gene Expression in Breast Cancer
Author Information
Author(s): N.R. Lemoinel, D.M. Barnes, D.P. Hollywood, C.M. Hughes, P. Smith, E. Dublin, S.A. Prigent, W.J. Gullick, H.C. Hurst
Primary Institution: ICRF Oncology Group, Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Are there abnormalities in the structure and/or expression of the ERBB3 receptor in human breast cancer?
Conclusion
ERBB3 is overexpressed in approximately 22% of breast cancer cases, but this overexpression does not correlate with patient survival.
Supporting Evidence
- ERBB3 shows stronger immunoreactivity in 22% of primary breast cancer cases compared to normal tissue.
- High expression of ERBB3 is positively associated with the presence of lymph node metastases.
- Overexpression of ERBB3 appears to result from increased levels of gene transcription.
Takeaway
This study looked at a gene called ERBB3 in breast cancer and found that some tumors have too much of it, but having more doesn't mean patients will live longer.
Methodology
The study used nucleic acid analysis and immunohistochemistry on tumor samples from 195 breast cancer patients.
Limitations
The study did not find a correlation between ERBB3 expression and patient survival, indicating that more research is needed to understand its role.
Participant Demographics
The study included 195 patients with primary infiltrating breast cancer, with a medium follow-up of 10.04 years.
Statistical Information
P-Value
0.02
Statistical Significance
p=0.02
Want to read the original?
Access the complete publication on the publisher's website